This web site is part of the Business Intelligence Division of Informa PLC
This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
Drug Names(s): fosphenytoin sodium injection, Fostoin (Japan)
Description: Fosphenytoin is a prodrug of phenytoin and accordingly, its anticonvulsant effects areattributable to phenytoin. The mechanism of action of phenytoin is not definitely known, but extensive research strongly suggests that its main mechanism is to block frequency-, use- and voltage-dependent neuronal sodium channels, and therefore limit repetitive firing of action potentials.
After IV administration to mice, fosphenytoin blocked the tonic phase of maximalelectroshock seizures at doses equivalent to those effective for phenytoin. In addition toits ability to suppress maximal electroshock seizures in mice and rats, phenytoin exhibitsanticonvulsant activity against kindled seizures in rats, audiogenic seizures in mice, andseizures produced by electrical stimulation of the brainstem in rats.
Pfizer and Warner-Lambert
Pfizer announced the acquisition of Warner-Lambert for $90.27 billion on February 7, 2000.
Pfizer and Eisai
In 2002, Eisai acquired exclusive U.S. rights from Pfizer Inc to promote Cerebyx. Financial terms were not disclosed.
Eisai and Nobelpharma
Fostoin was developed in Japan by Nobelpharma. The drug will be marketed by Eisai and co-promoted by both companies under a previously concluded marketing agreement.
Partners: Eisai Co., Ltd. Nobelpharma Co., Ltd.
Pink Sheet Eisai acquires Cerebyx from Pfizer
Additional information available to subscribers only: